Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

U.S. FDA grants Fast Track designation for Polyphor’s innovative immuno-oncology candidate balixafortide in combination with eribulin as third line therapy for metastatic breast cancer

biospaceApril 23, 2018

Tag: FDA , balixafortide

PharmaSources Customer Service